The effects of peripheral and central high insulin on brain insulin signaling and amyloid-β in young and old APP/PS1 mice

Journal of Neuroscience

Volumn 36, Issue 46, 2016, Pages 11704-11715

  Stanley, Molly ^a   Macauley, Shannon L ^a   Caesar, Emily E ^a   Koscal, Lauren J ^a   Moritz, Will ^a   Robinson, Grace O ^a   Roh, Joseph ^a   Keyser, Jennifer ^a   Jiang, Hong ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloid beta; APP PS1; Hyperinsulinemic euglycemic clamps; Insulin; Insulin receptor signaling; Microdialysis

Indexed keywords

AMYLOID BETA PROTEIN; GLUCOSE; INSULIN; INSULINASE; LACTIC ACID; PROTEIN KINASE B; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; PRESENILIN 1, MOUSE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HIPPOCAMPUS; HYPERINSULINEMIA; IMMUNOHISTOCHEMISTRY; INSULIN SENSITIVITY; INTERSTITIAL FLUID; INTRACELLULAR SIGNALING; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING; AGING; ANIMAL; BLOOD; GENETICS; HYPERINSULINISM; INSULIN RESISTANCE; METABOLISM; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TRANSGENIC MOUSE;

AGING; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; FEMALE; HIPPOCAMPUS; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL; PRESENILIN-1; SIGNAL TRANSDUCTION;

EID: 84996557767     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2119-16.2016     Document Type: Article

References (55)

1. Ayala JE,Bracy DP,McGuinness OP,Wasserman DH (2006) Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55:390–397.
2. Banks WA (2004) The source of cerebral insulin. Eur J Pharmacol 490:5–12.
3. Banks WA,Jaspan JB,Kastin AJ (1997) Selective,physiological transport of insulin across the blood–brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides 18:1257–1262.
4. Baura GD,Foster DM,Porte D Jr,Kahn SE,Bergman RN,Cobelli C,Schwartz MW (1993) Saturable transport of insulin from plasma into the central nervous system of dogs in vivo: a mechanism for regulated insulin delivery to the brain. J Clin Invest 92:1824–1830.
5. Berhane F,Fite A,Daboul N,Al-Janabi W,Msallaty Z,Caruso M,Lewis MK,Yi Z,Diamond MP,Abou-Samra AB,Seyoum B (2015) Plasma lactate levels increase during hyperinsulinemic euglycemic clamp and oral glucose tolerance test. J Diabetes Res 2015:102054.
6. Bero AW,Yan P,Roh JH,Cirrito JR,Stewart FR,Raichle ME,Lee JM,Holtzman DM (2011) Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci 14:750–756.
7. Bomfim TR,Forny-Germano L,Sathler LB,Brito-Moreira J,Houzel JC,Decker H,Silverman MA,Kazi H,Melo HM,McClean PL,Holscher C,Arnold SE,Talbot K,Klein WL,Munoz DP,Ferreira ST,De Felice FG (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease-associated Abeta oligomers. J Clin Invest 122:1339–1353.
8. Borchelt DR,Ratovitski T,van Lare J,Lee MK,Gonzales V,Jenkins NA,Copeland NG,Price DL,Sisodia SS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19:939–945.
9. Cirrito JR,May PC,O’Dell MA,Taylor JW,Parsadanian M,Cramer JW,Audia JE,Nissen JS,Bales KR,Paul SM,DeMattos RB,Holtzman DM (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 23:8844–8853.
10. Clodfelder-Miller B,De Sarno P,Zmijewska AA,Song L,Jope RS (2005) Physiological and pathological changes in glucose regulate brain Akt and glycogen synthase kinase-3. J Biol Chem 280:39723–39731.
11. Craft S,Peskind E,Schwartz MW,Schellenberg GD,Raskind M,Porte D Jr (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50:164–168.
12. Deane R,Du Yan S,Submamaryan RK,LaRue B,Jovanovic S,Hogg E,Welch D,Manness L,Lin C,Yu J,Zhu H,Ghiso J,Frangione B,Stern A,Schmidt AM,Armstrong DL,Arnold B,Liliensiek B,Nawroth P,Hofman F,et al. (2003) RAGE mediates amyloid-beta peptide transport across the blood–brain barrier and accumulation in brain. Nat Med 9:907–913.
13. De Felice FG,Vieira MN,Bomfim TR,Decker H,Velasco PT,Lambert MP,Viola KL,Zhao WQ,Ferreira ST,Klein WL (2009) Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 106: 1971–1976.
14. DeMattos RB,Bales KR,Cummins DJ,Dodart JC,Paul SM,Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 98:8850–8855.
15. Dummler B,Tschopp O,Hynx D,Yang ZZ,Dirnhofer S,Hemmings BA (2006) Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol Cell Biol 26:8042–8051.
16. Fishel MA,Watson GS,Montine TJ,Wang Q,Green PS,Kulstad JJ,Cook DG,Peskind ER,Baker LD,Goldgaber D,Nie W,Asthana S,Plymate SR,Schwartz MW,Craft S (2005) Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol 62:1539–1544.
17. Freude S,Plum L,Schnitker J,Leeser U,Udelhoven M,Krone W,Bruning JC,Schubert M (2005) Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 54:3343–3348.
18. Fujisawa Y,Sasaki K,Akiyama K (1991) Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol Psychiatry 30:1219–1228.
19. Gasparini L,Gouras GK,Wang R,Gross RS,Beal MF,Greengard P,Xu H (2001) Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 21:2561–2570.
20. Harris RA,Tindale L,Lone A,Singh O,Macauley SL,Stanley M,Holtzman DM,Bartha R,Cumming RC (2016) Aerobic glycolysis in the frontal cortex correlates with memory performance in wild-type mice but not the APP/PS1 mouse model of cerebral amyloidosis. J Neurosci 36:1871–1878.
21. Holtzman DM,Morris JC,Goate AM (2011) Alzheimer’s disease: the challenge of the second century. Sci Transl Med 3:3002369.
22. Kuusisto J,Koivisto K,Mykkanen L,Helkala EL,Vanhanen M,Hanninen T,Kervinen K,Kesaniemi YA,Riekkinen PJ,Laakso M (1997) Association between features of the insulin resistance syndrome and Alzheimer’s disease independently of apolipoprotein E4 phenotype: cross sectional population based study. Br Med J 315:1045–1049.
23. Luchsinger JA,Tang MX,Shea S,Mayeux R (2004) Hyperinsulinemia and risk of Alzheimer disease. Neurology 63:1187–1192.
24. Ma J,Zhang W,Wang HF,Wang ZX,Jiang T,Tan MS,Yu JT,Tan L (2016) Peripheral blood adipokines and insulin levels in patients with Alzheimer’s disease: a replication study and meta-analysis. Curr Alzheimer Res 13:223–233.
25. Macauley SL,Stanley M,Caesar EE,Yamada SA,Raichle ME,Perez R,Mahan TE,Sutphen CL,Holtzman DM (2015) Hyperglycemia modulates extracellular amyloid-beta concentrations and neuronal activity in vivo. J Clin Invest 125:2463–2467.
26. Maness LM,Banks WA,Podlisny MB,Selkoe DJ,Kastin AJ (1994) Passage of human amyloid β-protein 1–40 across the murine blood–brain barrier. Life Sci 55:1643–1650.
27. Martel CL,Mackic JB,McComb JG,Ghiso J,Zlokovic BV (1996) Blood– brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer’s amyloid beta in guinea pigs. Neurosci Lett 206:157–160.
28. McNay EC,Ong CT,McCrimmon RJ,Cresswell J,Bogan JS,Sherwin RS (2010) Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neurobiol Learn Mem 93:546–553.
29. Mehran AE,Templeman NM,Brigidi GS,Lim GE,Chu KY,Hu X,Botezelli JD,Asadi A,Hoffman BG,Kieffer TJ,Bamji SX,Clee SM,Johnson JD (2012) Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. Cell Metab 16:723–737.
30. Moloney AM,Griffin RJ,Timmons S,O’Connor R,Ravid R,O’Neill C (2010) Defects in IGF-1 receptor,insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31:224–243.
31. Mosthaf L,Grako K,Dull TJ,Coussens L,Ullrich A,McClain DA (1990) Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J 9:2409–2413.
32. Musiek ES,Holtzman DM (2015) Three dimensions of the amyloid hypothesis: time,space and ‘wingmen.’ Nat Neurosci 18:800–806.
33. Pandini G,Pace V,Copani A,Squatrito S,Milardi D,Vigneri R (2013) Insulin has multiple antiamyloidogenic effects on human neuronal cells. Endocrinology 154:375–387.
34. Plum L,Schubert M,Brüning JC (2005) The role of insulin receptor signaling in the brain. Trends Endocrinol Metab 16:59–65.
35. Qiu WQ,Walsh DM,Ye Z,Vekrellis K,Zhang J,Podlisny MB,Rosner MR,Safavi A,Hersh LB,Selkoe DJ (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273:32730–32738.
36. Sajan M,Hansen B,Ivey R 3rd,Sajan J,Ari C,Song S,Braun U,Leitges M,Farese-Higgs M,Farese RV (2016) Brain insulin signaling is increased in insulin-resistant states and decreases in FoxOs and PGC-1alpha and increases in Abeta1–40.42 and phospho-tau may abet Alzheimer development. Diabetes 65:1892–1903.
37. Sartorius T,Peter A,Heni M,Maetzler W,Fritsche A,Häring HU,Hennige AM (2015) The brain response to peripheral insulin declines with age: a contribution of the blood–brain barrier? PLoS One 10:e0126804.
38. Selkoe DJ (2004) Cell biology of protein misfolding: the examples of Alzheimer’s and Parkinson’s diseases. Nat Cell Biol 6:1054–1061.
39. Shiiki T,Ohtsuki S,Kurihara A,Naganuma H,Nishimura K,Tachikawa M,Hosoya K,Terasaki T (2004) Brain insulin impairs amyloid-beta(1–40) clearance from the brain. J Neurosci 24:9632–9637.
40. Sims-Robinson C,Kim B,Rosko A,Feldman EL (2010) How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6:551–559.
41. Sperling RA,Aisen PS,Beckett LA,Bennett DA,Craft S,Fagan AM,Iwatsubo T,Jack CR Jr,Kaye J,Montine TJ,Park DC,Reiman EM,Rowe CC,Siemers E,Stern Y,Yaffe K,Carrillo MC,Thies B,Morrison-Bogorad M,Wagster MV,et al. (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:280–292.
42. Stanley M,Macauley SL,Holtzman DM (2016) Changes in insulin and insulin signaling in Alzheimer’s disease: cause or consequence? J Exp Med 213:1375–1385.
43. Stein LJ,Dorsa DM,Baskin DG,Figlewicz DP,Porte D Jr,Woods SC (1987) Reduced effect of experimental peripheral hyperinsulinemia to elevate cerebrospinal fluid insulin concentrations of obese Zucker rats. Endocrinology 121:1611–1615.
44. Stöhr O,Schilbach K,Moll L,Hettich MM,Freude S,Wunderlich FT,Ernst M,Zemva J,Brüning JC,Krone W,Udelhoven M,Schubert M (2013) Insulin receptor signaling mediates APP processing and beta-amyloid accumulation without altering survival in a transgenic mouse model of Alzheimer’s disease. Age 35:83–101.
45. Talbot K,Wang HY,Kazi H,Han LY,Bakshi KP,Stucky A,Fuino RL,Kawaguchi KR,Samoyedny AJ,Wilson RS,Arvanitakis Z,Schneider JA,Wolf BA,Bennett DA,Trojanowski JQ,Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance,IRS-1 dysregulation,and cognitive decline. J Clin Invest 122:1316–1338.
46. Wadman M (2012) US government sets out Alzheimer’s plan. Nature 485: 426–427.
47. Watson GS,Peskind ER,Asthana S,Purganan K,Wait C,Chapman D,Schwartz MW,Plymate S,Craft S (2003) Insulin increases CSF Abeta42 levels in normal older adults. Neurology 60:1899–1903.
48. Weiland M,Bahr F,Höhne M,Schürmann A,Ziehm D,Joost HG (1991) The signaling potential of the receptors for insulin and insulin-like growth factor I (IGF-I) in 3T3–L1 adipocytes: comparison of glucose transport activity,induction of oncogene c-fos,glucose transporter mRNA,and DNA-synthesis. J Cell Physiol 149:428–435.
49. Willette AA,Johnson SC,Birdsill AC,Sager MA,Christian B,Baker LD,Craft S,Oh J,Statz E,Hermann BP,Jonaitis EM,Koscik RL,La Rue A,Asthana S,Bendlin BB (2015) Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement 11:504–510.
50. Wojtaszewski JF,Hansen BF,Gade,Kiens B,Markuns JF,Goodyear LJ,Richter EA (2000) Insulin signaling and insulin sensitivity after exercise in human skeletal muscle. Diabetes 49:325–331.
51. Xie L,Kang H,Xu Q,Chen MJ,Liao Y,Thiyagarajan M,O’Donnell J,Christensen DJ,Nicholson C,Iliff JJ,Takano T,Deane R,Nedergaard M (2013) Sleep drives metabolite clearance from the adult brain. Science 342:373–377.
52. Yarchoan M,Toledo JB,Lee EB,Arvanitakis Z,Kazi H,Han LY,Louneva N,Lee VM,Kim SF,Trojanowski JQ,Arnold SE (2014) Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer’s disease and tauopathies. Acta Neuropathol 128: 679–689.
53. Zhao L,Teter B,Morihara T,Lim GP,Ambegaokar SS,Ubeda OJ,Frautschy SA,Cole GM (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer’s disease intervention. J Neurosci 24:11120–11126.
54. Zhao WQ,De Felice FG,Fernandez S,Chen H,Lambert MP,Quon MJ,Krafft GA,Klein WL (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22:246–260.
55. Zuchero YJ,Chen X,Bien-Ly N,Bumbaca D,Tong RK,Gao X,Zhang S,Hoyte K,Luk W,Huntley MA,Phu L,Tan C,Kallop D,Weimer RM,Lu Y,Kirkpatrick DS,Ernst JA,Chih B,Dennis MS,Watts RJ (2016) Discovery of novel blood–brain barrier targets to enhance brain uptake of therapeutic antibodies. Neuron 89:70–82.